KD Logo

Gain Therapeutics Inc [GANX] CFO and Interim CEO makes an insider purchase of 14,400 shares worth 14544.0.

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Gain Therapeutics Inc shares valued at $14,544 were purchased by Mack Gene on Aug 09 ’24. At $1.01 per share, Mack Gene acquired 14,400 shares. The insider’s holdings grew to 14,400 shares worth approximately $31392.000000000004 following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, Islam Khalid purchased 50,000 shares, netting a total of over 49,940 in proceeds. Following the buying of shares at $1.00 each, the insider now holds 50,000 shares.

Before that, RICHMAN ERIC I had added 17,000 shares to its account. In a trade valued at $20,670, the Director bought Gain Therapeutics Inc shares for $1.22 each. Upon closing the transaction, the insider’s holdings increased to 17,000 shares, worth approximately $0.63 million.

Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid April. As of April 12, 2021, BTIG Research has initiated its “Buy” rating for GANX.

Analyzing GANX Stock Performance

During the last five days, there has been a drop of approximately -18.66%. Over the course of the year, Gain Therapeutics Inc shares have dropped approximately -33.23%. Shares of the company reached a 52-week high of $5.33 on 02/07/24 and a 52-week low of $0.89 on 08/13/24. A 50-day SMA is recorded $1.80, while a 200-day SMA reached $2.56. Nevertheless, trading volume fell to 0.5 million shares from 0.36 million shares the previous day.

Support And Resistance Levels for Gain Therapeutics Inc (GANX)

According to the 24-hour chart, there is a support level at 2.01, which, if violated, would cause prices to drop to 1.83. In the upper region, resistance lies at 2.47. The next price resistance is at 2.75. RSI (Relative Strength Index) is 47.51 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.11, which suggests the price will decrease in the coming days. Percent R is at 80.80%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Most Popular